// App-Quantinova.ai

172 : Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Helena Marzo-Ortega

  • Clarence W Legerton

  • Joachim Sieper

  • Alan Kivitz

  • Ricardo Blanco

  • Martin Cohen

  • Evie Maria Delicha

  • Susanne Rohrer

  • Hanno B Richards

Medical Centers

  • Rheumatology, Barts Health NHS Trust, London, UNITED KINGDOM

  • NIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM

  • Low Country Rheumatology, Articularis Healthcare, Charleston, United States

  • Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany

  • Altoona Center for Clinical Research, Duncansville, PA

  • Hematology, Hospital Universitario Marques de Valdecilla, Santander, Spain

  • McGill University Health Centre, Montreal, QC, Canada

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • United States

  • Germany

  • Spain

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Multinational

Phase

  • III

Study Id's

  • NCT01649375

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved